Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Legend Biotech

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review

Here's a roundup of top developments in the biotech space over the last 24 hours:

Analyst Ratings For Legend Biotech

Analyst Ratings For Legend Biotech

Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment

Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that Legend Biotech’s Cilta-cel CAR-T cell therapy product was approved by the FDA on Monday, and could become a major cash cow for GenScript Biotech By Molly…

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution

Here's a roundup of top developments in the biotech space over the last 24 hours:

FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy

FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ:

inkl

Read news from The Economist, FT, and more,
with one subscription

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Canaccord Genuity

Monster Beverage

Compass Pathways

Emerson Electric

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

314,360 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play